Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Imugene ( (AU:IMU) ) has provided an update.
Imugene Limited announced amendments to its existing convertible notes and introduced new convertible notes and warrants valued at A$2.5 million and A$2.75 million, respectively, in collaboration with CVI Investments, Inc. The financial adjustments aim to enhance the company’s cash flow management and provide flexibility, supporting operational stability during the term of the notes. By issuing the new financial instruments under its existing ASX Listing Rule capacity without needing shareholder approval, Imugene strengthens its financial standing and market positioning in the immuno-oncology sector.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a clinical stage immuno-oncology firm specializing in developing novel immunotherapies aimed at activating the immune system of cancer patients to treat and eliminate tumors. Its portfolio includes platform technologies targeting blood cancers and tumor eradication through innovative mechanisms, including its off-the-shelf CAR T drug azer-cel for CD19-positive cancers.
Average Trading Volume: 2,053,203
Technical Sentiment Signal: Sell
Current Market Cap: A$99.33M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.